Compare iShares MSCI Hong Kong ETF (EWH) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Hong Kong ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? iShares MSCI Hong Kong ETF trades at $21.72 (market cap $1.15B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 111.4× iShares MSCI Hong Kong ETF's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, iShares MSCI Hong Kong ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Hong Kong ETF for 61 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| EWH | VRTX | |
|---|---|---|
Market Cap | $1.15B | $128.16B |
Volume | 2,444,357 | 806,603 |
Sector | Broad Market / Factor | Health |
52-Week High | $24.55 | $557.96 |
52-Week Low | $20.66 | $407.37 |
Typical Hold Time | 61 Days | 120 Days |
Enterprise Value | — | $122.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWH trades at $21.58, down 0.19% with a bearish technical signal as moving averages show strong selling pressure. The ETF tracks Hong Kong's Hang Seng Index, which has faced significant volatility due to US-China tensions and Federal Reserve policy concerns. Recent institutional selling by Empowered Funds LLC (70.2% reduction in Q2 2026) reflects cautious sentiment toward Hong Kong markets.
Outlook remains challenged by geopolitical risks and Hong Kong market volatility, though oversold RSI levels suggest potential for near-term technical bounce. Key risks include continued US-China tensions and Fed policy uncertainty, while opportunities exist if Hong Kong equities stabilize. The ETF lacks fundamental metrics as it tracks an index rather than operating as a standalone company.
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI Hong Kong ETF
EWH tracks the MSCI Hong Kong 25/50 Index, providing broad exposure to large and mid-cap companies listed in Hong Kong. It focuses on the established pillars of the local economy, with heavy weightings in financials, real estate, and utilities, serving as a single-country diversification tool.
Read more on EWH →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
